Literature DB >> 19825785

Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study.

M W Fei1, E J Kim, C A Sant, L G Jarlsberg, J L Davis, A Swartzman, L Huang.   

Abstract

BACKGROUND: Although the use of antiretroviral therapy has led to dramatic declines in AIDS-associated mortality, Pneumocystis pneumonia (PCP) remains a leading cause of death in HIV-infected patients.
OBJECTIVES: To measure mortality, identify predictors of mortality at time of illness presentation and derive a PCP mortality prediction rule that stratifies patients by risk for mortality.
METHODS: An observational cohort study with case note review of all HIV-infected persons with a laboratory diagnosis of PCP at San Francisco General Hospital from 1997 to 2006.
RESULTS: 451 patients were diagnosed with PCP on 524 occasions. In-hospital mortality was 10.3%. Multivariate analysis identified five significant predictors of mortality: age (adjusted odds ratio (AOR) per 10-year increase, 1.69; 95% CI 1.08 to 2.65; p = 0.02); recent injection drug use (AOR 2.86; 95% CI 1.28 to 6.42; p = 0.01); total bilirubin >0.6 mg/dl (AOR 2.59; 95% CI 1.19 to 5.62; p = 0.02); serum albumin <3 g/dl (AOR 3.63; 95% CI 1.72-7.66; p = 0.001); and alveolar-arterial oxygen gradient >or=50 mm Hg (AOR 3.02; 95% CI 1.41 to 6.47; p = 0.004). Using these five predictors, a six-point PCP mortality prediction rule was derived that stratifies patients according to increasing risk of mortality: score 0-1, 4%; score 2-3, 12%; score 4-5, 48%.
CONCLUSIONS: The PCP mortality prediction rule stratifies patients by mortality risk at the time of illness presentation and should be validated as a clinical tool.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19825785      PMCID: PMC2788120          DOI: 10.1136/thx.2009.117846

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  33 in total

1.  Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia.

Authors:  J R Curtis; P R Yarnold; D N Schwartz; R A Weinstein; C L Bennett
Journal:  Am J Respir Crit Care Med       Date:  2000-08       Impact factor: 21.405

Review 2.  Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.

Authors:  J E Kaplan; D Hanson; M S Dworkin; T Frederick; J Bertolli; M L Lindegren; S Holmberg; J L Jones
Journal:  Clin Infect Dis       Date:  2000-04       Impact factor: 9.079

3.  Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia.

Authors:  T L Benfield; J Helweg-Larsen; D Bang; J Junge; J D Lundgren
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

4.  Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia.

Authors:  Alison Morris; Robert M Wachter; John Luce; Joan Turner; Laurence Huang
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

5.  A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era.

Authors:  A M Arozullah; P R Yarnold; R A Weinstein; N Nwadiaro; T B McIlraith; J S Chmiel; A M Sipler; C Chan; M B Goetz; D N Schwartz; C L Bennett
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

6.  US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era.

Authors:  Constance R Uphold; Maria Deloria-Knoll; Frank J Palella; Jorge P Parada; Joan S Chmiel; Laura Phan; Charles L Bennett
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

7.  Combined APACHE II score and serum lactate dehydrogenase as predictors of in-hospital mortality caused by first episode Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Authors:  C A Benson; J Spear; D Hines; J C Pottage; H A Kessler; G M Trenholme
Journal:  Am Rev Respir Dis       Date:  1991-08

8.  Serum bilirubin levels on ICU admission are associated with ARDS development and mortality in sepsis.

Authors:  R Zhai; C C Sheu; L Su; M N Gong; P Tejera; F Chen; Z Wang; M P Convery; B T Thompson; D C Christiani
Journal:  Thorax       Date:  2009-05-28       Impact factor: 9.139

9.  Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii Pneumonia in the United States (1986 to 2005).

Authors:  Colleen F Kelley; William Checkley; David M Mannino; Carlos Franco-Paredes; Carlos Del Rio; Fernando Holguin
Journal:  Chest       Date:  2009-03-02       Impact factor: 9.410

10.  Retrospective review of Pneumocystis jirovecii pneumonia over two decades.

Authors:  J Travis; E Hart; J Helm; T Duncan; J Vilar
Journal:  Int J STD AIDS       Date:  2009-03       Impact factor: 1.359

View more
  30 in total

Review 1.  Histone-modifying enzymes, histone modifications and histone chaperones in nucleosome assembly: Lessons learned from Rtt109 histone acetyltransferases.

Authors:  Jayme L Dahlin; Xiaoyue Chen; Michael A Walters; Zhiguo Zhang
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-11-03       Impact factor: 8.250

Review 2.  HIV-associated Pneumocystis pneumonia.

Authors:  Laurence Huang; Adithya Cattamanchi; J Lucian Davis; Saskia den Boon; Joseph Kovacs; Steven Meshnick; Robert F Miller; Peter D Walzer; William Worodria; Henry Masur
Journal:  Proc Am Thorac Soc       Date:  2011-06

Review 3.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

4.  Virtual Screening of Phytochemicals to Novel Target (HAT) Rtt109 in Pneumocystis Jirovecii using Bioinformatics Tools.

Authors:  Ramya Sugumar; Abhinand Ponneri Adithavarman; Anusha Dakshinamoorthi; Darling Chellathai David; Padmavathi Kannan Ragunath
Journal:  J Clin Diagn Res       Date:  2016-03-01

5.  Pneumocystis jirovecii Rtt109, a novel drug target for Pneumocystis pneumonia in immunosuppressed humans.

Authors:  Jayme L Dahlin; Theodore Kottom; Junhong Han; Hui Zhou; Michael A Walters; Zhiguo Zhang; Andrew H Limper
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

6.  Characterization of the Pneumocystis carinii histone acetyltransferase chaperone proteins PcAsf1 and PcVps75.

Authors:  Jakrapun Pupaibool; Theodore J Kottom; Kelly Bouchonville; Andrew H Limper
Journal:  Infect Immun       Date:  2013-04-08       Impact factor: 3.441

Review 7.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

8.  Substance use is independently associated with pneumonia severity in persons living with the human immunodeficiency virus (HIV).

Authors:  Sarah E Jolley; David A Welsh
Journal:  Subst Abus       Date:  2019-03-18       Impact factor: 3.716

Review 9.  Clinical and translational research in pneumocystis and pneumocystis pneumonia.

Authors:  L Huang
Journal:  Parasite       Date:  2011-02       Impact factor: 3.000

10.  Multilocus microsatellite genotyping array for investigation of genetic epidemiology of Pneumocystis jirovecii.

Authors:  Christian M Parobek; Linda Y Jiang; Jaymin C Patel; Miriam J Alvarez-Martínez; Jose M Miro; William Worodria; Alfred Andama; Serena Fong; Laurence Huang; Steven R Meshnick; Steve M Taylor; Jonathan J Juliano
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.